FY2017 EPS Estimates for Pain Therapeutics, Inc. (PTIE) Boosted by Analyst

Pain Therapeutics, Inc. (NASDAQ:PTIE) – Equities research analysts at Gabelli upped their FY2017 earnings per share estimates for Pain Therapeutics in a report issued on Wednesday. Gabelli analyst K. Kedra now forecasts that the biopharmaceutical company will earn ($1.90) per share for the year, up from their prior estimate of ($2.20). Gabelli also issued estimates for Pain Therapeutics’ FY2018 earnings at ($2.50) EPS, FY2019 earnings at ($5.00) EPS, FY2020 earnings at ($4.70) EPS and FY2021 earnings at ($3.50) EPS.

Several other equities research analysts also recently weighed in on PTIE. Zacks Investment Research downgraded shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. ValuEngine downgraded shares of Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.

Shares of Pain Therapeutics (PTIE) opened at $7.80 on Friday. The firm has a market cap of $56.13, a P/E ratio of -4.24 and a beta of 2.11. Pain Therapeutics has a 1 year low of $3.10 and a 1 year high of $12.80.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter.

A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Pain Therapeutics, Inc. (NASDAQ:PTIE) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned 0.91% of Pain Therapeutics at the end of the most recent quarter. 35.99% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2018/01/13/fy2017-eps-estimates-for-pain-therapeutics-inc-ptie-boosted-by-analyst.html.

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Earnings History and Estimates for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply